Analysts See $-0.55 EPS for Quotient Limited (QTNT)

January 19, 2018 - By Ellis Scott

 Analysts See $ 0.55 EPS for Quotient Limited (QTNT)
Investors sentiment decreased to 1.42 in Q3 2017. Its down 6.98, from 8.4 in 2017Q2. It dived, as 7 investors sold Quotient Limited shares while 12 reduced holdings. 9 funds opened positions while 18 raised stakes. 21.37 million shares or 49.89% less from 42.64 million shares in 2017Q2 were reported.
Acuta Limited Liability reported 569,145 shares stake. The California-based Park West Asset Management Ltd Liability has invested 0.08% in Quotient Limited (NASDAQ:QTNT). Ameriprise Fincl Inc accumulated 1.92M shares or 0% of the stock. Colony Gp accumulated 13,360 shares or 0% of the stock. Vermont-based Birchview L P has invested 0.15% in Quotient Limited (NASDAQ:QTNT). Sio Ltd Limited Liability Company holds 6% or 2.34 million shares. Tower Rech Limited (Trc) accumulated 0% or 6,359 shares. Goldman Sachs Group has invested 0% in Quotient Limited (NASDAQ:QTNT). Perceptive Lc owns 0.7% invested in Quotient Limited (NASDAQ:QTNT) for 3.73M shares. Geode Capital Management Limited Company reported 73,052 shares. State Street accumulated 268,977 shares or 0% of the stock. Moreover, Credit Suisse Ag has 0% invested in Quotient Limited (NASDAQ:QTNT). Blackrock accumulated 1.66 million shares. Wells Fargo & Mn holds 1,863 shares or 0% of its portfolio. Royal Natl Bank Of Canada reported 0% of its portfolio in Quotient Limited (NASDAQ:QTNT).

Since August 15, 2017, it had 0 insider buys, and 4 selling transactions for $1.29 million activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.55 EPS on February, 5.They anticipate $0.51 EPS change or 48.11 % from last quarter’s $-1.06 EPS. After having $-0.58 EPS previously, Quotient Limited’s analysts see -5.17 % EPS growth. The stock increased 0.27% or $0.01 during the last trading session, reaching $3.73. About 165,001 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 16.87% since January 19, 2017 and is downtrending. It has underperformed by 33.57% the S&P500.

Quotient Limited (NASDAQ:QTNT) Ratings Coverage

Among 3 analysts covering Quotient (NASDAQ:QTNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quotient had 5 analyst reports since August 11, 2015 according to SRatingsIntel. BTIG Research initiated Quotient Limited (NASDAQ:QTNT) on Thursday, August 31 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, November 1 report. On Wednesday, November 4 the stock rating was maintained by UBS with “Buy”. The stock of Quotient Limited (NASDAQ:QTNT) has “Hold” rating given on Friday, August 14 by Zacks. Jefferies initiated Quotient Limited (NASDAQ:QTNT) rating on Tuesday, August 11. Jefferies has “Buy” rating and $30 target.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $169.94 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

Another recent and important Quotient Limited (NASDAQ:QTNT) news was published by which published an article titled: “Quotient Limited to Report Continued Progress on the Commercial Scale-Up of …” on July 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: